Register for free to
view the full innovation profile.
This technology is a series of innovative RSV reporter tools for high throughput screening of anti-viral drug candidates.
About
This
technology is a series of innovative RSV reporter tools for high throughput
screening of anti-viral drug candidates. Our reporter tools offer innovative
solutions for RSV drug discovery and vaccine development, with improved
sensitivity and robustness compared to conventional fluorescent assays. Additionally,
these tools are simplified, shortened versions of the viral genome, allowing safer
RSV research in lower BSL environments.
RSV is a
leading cause of respiratory infections in infants, young children, and elderly
worldwide. In the U.S. alone, there are 60,000–160,000 hospitalizations in
adults over 65 years old each year. Due to the limited duration of effect, high
cost, and suboptimal anti-inflammatory properties of existing RSV vaccines,
there is a pressing need to further develop enhanced RSV vaccines.
Key Benefits
·
Safer: Does not require high-level biosafety containment facilities.
· Improved Sensitivity:
High sensitivity compared to conventional
fluorescent assays, allowing detection of low concentrations of RSV virus in
samples
· High-Throughput
Screening: Can be used in high throughput
screening for RSV vaccine and drugs, allowing processing of large numbers of
samples with reduced cost and lab labor per sample
·
Quantification
of Viral Activity: Enables precise
quantification of viral activity
Applications
·
RSV Research and development
·
RSV anti-viral drug discovery
·
RSV vaccine development